INTRODUCTION
Treatment of thoracic malignancies is a rather diffi cult field of surgery. Earlier, some locally advanced diseases, for example, with invasion to the heart or great vessels, seemed to be inoperable. But when cooperating with cardiac surgeons and using car diopulmonary bypass, it became possible to help these patients. These operations are not of usual practice. (7) -6 patients. So we decided to share our experience in the surgical management of thoracic malignancies, using pump operations.
The study objective was to evaluate the efficacy of pump operations in locally advanced IIIB (T4N0 1M0) lung cancer and other thoracic malignancies and the results of treatment. (Table) . We had no complications after pump operations. Median survival of patients with lung cancer was 2.5 ± 0.5 years, in patients with angiosarcoma it was 3.5 ± 1.0 years. Fiveyear survival was 25%.
MATERIALS AND METHODS

In
DISCUSSION
In our series of pump operations we mean cardio pulmonary bypass (CPB) through canulating the ascending aorta and upper and lower vena cava. (5) re viewed their experience during approximately ten years, as in our study, and the pathology, for which they perform extendend pulmonary resections, was similar. Wiebe K. et al. showed results of sarcomas (n = 8), non small cell lung carcinomas (n = 3) and others (n = 2) (3), with 15% mortality rate, and ma jor complications, such as acute lung injury (n = 4), right heart failure (n = 1) and multiorgan failure (n = 1). The cumulative survival at 1, 3, and 5 years in patients presenting with sarcomas was 62.5% compared to 33%, 0%, and 0%, respectively, in pa tients with nonsmall cell carcinoma (n = 3).
Park B. J. et al. (2004) conducted a review of the results in 10 patients who underwent resection of thoracic malignancies that included either great vessel or the heart (4). Histologic diagnoses inclu ded soft tissue sarcoma (n = 7), squamous cell car cinoma (n = 1), malignant thymoma (n = 1), and mediastinal teratoma (n = 1). Structures resected included superior vena cava (n = 5), left atrium (n = 4), right atrium (n = 2), descending aorta (n = 1), and main pulmonary artery (n = 1). Six patients underwent postoperative systemic therapy. The overall median survival was 21.7 months (range 3.2 to 69 months) and was 33.3 months (range 3.7 to 69 months) for patients who had R0 or R1 re section (4) . These data are similar to ours, as 5 of 6 patients recieved adjuvant chemo or radiothera py, and median survival in our series was 2.5 years for lung cancer patiens, and 3.5 years for sarcoma. Byrne J. G. et al. (2004) (5) review fourteen conse cutive patients who underwent CPB during the re section of locally advanced thoracic malignancies. It is interesting that 6 of 14 patients (43%) required emergent institution of CPB due to injury of the superior vena cava (2 patients), inferior vena cava (2 patients), or pulmonary artery (2 patients). The operative mortality rate was 1 of 14 patients (7%) due to pulmonary embolism. The overall 1year, 3year, and 5year survival rates were 57%, 36%, and 21%, respectively. This article shows that the availability of CPB also provides a safety net in the event of injury to vascular structures during tumor resection (5). In our patients, all of them were ope rated with planned CPB, so there were no injuries of great vessels.
Vaporciyan A. A. et al. (2002) (6) reviewed the study where nineteen patients were included. Eleven patients underwent surgery with curative intent, and eight underwent surgery with palliative intent. Two patients (11%) died in the hospital after resection with palliative intent. Major complications occurred in 11 patients (58%); the most common major com plications were pneumonia (n = 7 patients), medias tinal hematoma (n = 4 patients), and acute respira tory distress syndrome (n = 2 patients). The overall 1 and 2year survival rates were 65% and 45%, re spectively (6) . In our series we perform operations only with curative intent, so we had no postoperative mortality, maybe due to better patients' condition.
Kodama K. et al. (2000) (7) performed opera tions for tumors invading the upper airway, left at rium or main pulmonary artery with percutaneous cardiopulmonary support (PCPS) stand by support available. Of 15 cases with PCPS stand by, 6 patients actually underwent operation using PCPS. There were three esophageal cancers invading the carina, two lung neoplasms with left atrial invasion and one neoplasm extending to the main pulmonary artery. One of three patients with esophageal can cer had massive bleeding in the trachea resulting in airway obstruction. PCPS should be the accepted technique for patients with advanced thoracic ma lignancies in whom cardiac arrest or ventilation support is thought to be necessary for the complete removal of the tumor (7). This article shows cases of esophageal cancer, managed with support or some kind of pump operation -PCPS.
All reviewed articles show more or less similar data and results, and conclude that CPB operations could be done with acceptable risk. The different thing in our material is that we had no complica tions. It is difficult to say why: maybe due to a low number of cases, or due to good patients selection.
We got 5year survival 25%, patients' benefit from surgical treatment, compared to the con servative treatment - Tan 2. Pump operations and adjuvant treatment may prolong the median survival in IIIB (T4N01M0) lung cancer patients by 2.5 ± 0.5 years and in an giosarcoma patients by 3.5 ± 1.0 years.
